Therapeutic ribozymes: Principles and applications

BioDrugs

Volumn 9, Issue 1, 1998, Pages 1-10

  Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; RIBOZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL RESEARCH; DRUG RESEARCH; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA METABOLISM;

EID: 0031963232     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809010-00001     Document Type: Review

References (56)

1. Kruger K, Grabowski PJ, Zaug AJ, et al. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982; 31: 147-57
2. Guerrier-Takada C, Gardiner K, Marsh T, et al. The RNA moiety of ribonuclease P is the catalylic subunit of the enzyme. Cell 1983; 35: 849-57
3. Cech TR. Ribozyme engineering. Curr Opin Struct Biol 1992; 2: 605-9
4. Rossi JJ. Making ribozymes work in cells. Curr Biol 1994; 4: 469-71
5. Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature 1992; 371: 619-22
6. Young B, Herschlag D, Cech TR. Mutations in a nonconserved sequence of the Tetrahymena ribozyme increase activity and specificity. Cell 1991; 29: 10159-71
7. Dahm SC, Derrick WB, Uhlenbeck OC. Evidence for the role of solvated metal hydroxide in the hammerhead cleavage mechanism. Biochemistry 1993; 32: 13040-5
8. Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 1990; 29: 10695-702
9. Goodchild J, Kohli V. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate. Arch Biochem Biophys 1991; 284: 386-91
10. Hendry P, McCall MJ, Santiago FS, et al. A ribozyme with DNA in the hybridising arms displays enhanced cleavage ability. Nucleic Acids Res 1992; 20: 5737-41
11. Paolella G, Sproat BS, Lamond AI. Nuclease resistant ribozymes with high catalytic activity. EMBO J 1992; 11: 1913-9
12. Taylor NR, Kaplan BE, Swiderski P, et al. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res 1992; 20: 4559-65
13. Bratty J, Chartrand P, Ferbeyre G, et al. The hammerhead RNA domain, a model ribozyme. Biochim Biophys Acta 1993; 1216: 345-9
14. Heidenreich O, Benseler P, Fahrenholz A, et al. High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates. J Biol Chem 1994; 269: 2131-8
15. Jarvis TC, Wincott FE, Laverna JA, et al. Optimizing the cell efficacy of synthetic ribozymes: site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J Biol Chem 1996; 271: 29107-12
16. Hertel KJ, Herschlag D, Uhlenbeck OC. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry 1994; 33: 3374-85
17. Hertel KJ, Uhlenbeck OC. The internal equilibrium of the hammerhead ribozyme reaction. Biochemistry 1995; 34: 1744-9
18. Dropulic B, Lin NH, Martin MA, et al. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J Virol 1992; 66: 1432-41
19. Dropulic B, Jeang KT. A virus model for examining the intracellular efficiency of a ribozyme targeted to HIV-1. Methods: a Companion to Methods in Enzymology 1993; 5: 43-9
20. Xing Z, Whitton JL. An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield. J Virol 1993; 67: 1840-7
21. Bertrand E, Pictet R, Frange T. Can hammerhead ribozymes be efficient tools to inactivate gene function? [published erratum appears in Nucleic Acids Res 1994 Apr 11; 22 (7): 1326]. Nucleic Acids Res 1994; 22: 293-300
22. Sullenger B, Cech TR. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 1993; 262: 1566-9
23. Cameron FH, Jennings PA. Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci USA 1989; 86: 9139-43
24. Steinecke P, Herget T, Schreier PH. Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo. EMBO J 1992; 11: 1525-30
25. Zhao JJ, Pick L. Generating loss-of-function phenotypes of the fushi tarazu gene with a targeted ribozyme in Drosophila. Nature 1993; 365: 448-51
26. Efrat S, Fusco-DeMane M, Wu Y-J, et al. Ribozyme-mediated attenuation of pancreatic beta-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion. Proc Natl Acad Sci USA 1994; 91: 2051-5
27. Larsson S, Hotchkiss G, Andang M, et al. Reduced β2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res 1994; 22: 2242-8
28. Sarver N, Cantin EM, Chang PS, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990; 247: 1222-5
29. Zhou C, Bahner IC, Larson GP, et al. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994; 149: 33-9
30. Bauer G, Valdez P, Kearns K, et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 1997; 89 (7): 2259-67
31. Chen CJ, Banerjea AC, Harmison GG, et al. Multitargetribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication: potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 1992; 20: 4581-9
32. Crisell P, Thompson S, James W. Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro. Nucleic Acids Res 1993; 21: 5251-5
33. Dropulic B, Hermankova M, Pitha PM. A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci USA 1996; 93: 11103-8
34. Lo KM, Biasolo MA, Dehni G, et al. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 1992; 190: 176-83
35. Ojwang JO, Hampel A, Looney DJ, et al. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 1992; 89: 10802-6
36. Weerasinghe M, Liem SR, Asad S, et al. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991; 65: 5531-4
37. Yamada O, Yu M, Yee JK, et al. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther 1994; 1: 38-45
38. Yu M, Ojwang J, Yamada O, et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1 [published erratum appears in Proc Natl Acad Sci USA 1993 Sep 1: 90 (17): 8303]. Proc Natl Acad Sci USA 1993; 90: 6340-4
39. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-22
40. Lieber A, He CY, Polyak SJ, et al. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996; 70: 8782-91
41. Koizumi M, Kamiya H, Ohtsuka E. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Haras gene. Gene 1992; 117: 179-84
42. Li M, Lonial H, Citarella R, et al. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther 1996; 3: 221-9
43. Snyder DS, Wu Y, Wang JL, et al. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 1993; 82: 600-5
44. Shore SK, Nabissa PM, Reddy EP. Ribozyme-mediated cleavage of the BCR-ABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oncogene 1993; 8: 3183-8
45. Daly C, Coyle S, McBride S, et al. mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines. Cytotechnology 1996; 19: 199-205
46. Czubayko F, Schulte AM, Berchem GJ, et al. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 1996; 93: 14753-8
47. Kanazawa Y, Ohkawa K, Ueda K, et al. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 1996; 225: 570-6
48. Kilpatrick MW, Phylactou LA, Godfrey M, et al. Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts. Hum Mol Genet 1966; 5: 1939-44
49. Sioud M. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by peritoneal cells in vitro and in vivo. Eur J Immunol 1996; 26: 1026-31
50. Turck J, Pollock AS, Lee LK, et al. Matrix metalloproteinex 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 1996; 271: 15074-83
51. Jarvis TC, Alby LJ, Beaudry AA, et al. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. RNA 1996; 2: 419-28
52. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62: 191-217
53. Muzcyzka N. Curr Top Microbiol Immunol 1992; 158: 7-123
54. Bertrand EL, Rossi JJ. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein AI. EMBO J 1994; 13: 2904-12
55. Herschlag D, Khosla M, Tsuchihashi Z, et al. An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis [published erratum appears in EMBO J 1994 Aug 15; 13(16): 3926]. EMBO J 1994; 13: 2913-24
56. Tsuchihashi Z, Khoslo M, Herschlag D. Protein enhancement of hammerhead ribozyme catalysis. Science 1993; 262: 99-102